A pilot clinical trial was conducted in mild to moderate ulcerative colitis patients, who were requested to consume 500 mg of resveratrol for six weeks, showed significant reduction in inflammatory markers (tumor necrosis factor-alpha; TNF-α, high sensitivity C-reactive protein; hs-CRP, Nuclear factor-kappa B; NF-κB), clinical colitis activity index score, and increased antioxidant status with improving quality of life (QOL) [81,82]. Here, TNF is linked to colitis.